Cancer Research Horizons
Genghis Lloyd-Harris is currently serving in various roles within the fields of biotechnology, venture capital, and philanthropy. With experience in roles such as Investor-In-Residence at Cancer Research Horizons, Senior Advisor at Lean Life Science, Chairman at ClotProtect, and Senior Advisor at Abingworth, Lloyd-Harris has a strong background in the industry. Additionally, their previous experience at Credit Suisse First Boston and education from Harvard Graduate School of Business Administration, University of Melbourne, and Liverpool University Medical School further solidify their expertise in the field.
This person is not in any teams
Cancer Research Horizons
Cancer Research Horizons is Cancer Research UK's innovation engine. We take scientific breakthroughs from the lab bench to the bedside, translating them into effective treatments and diagnostics for cancer patients. To date, we’ve played an instrumental role in forming over 60 spin-out companies and bringing 11 new cancer drugs to market, borne out of our pioneering research. We are the second biggest licensor of cancer research treatments globally and are part of Cancer Research UK – the world’s largest medical research charity. With exclusive rights to over £300m of world-class cancer research we’re a unique and powerful partner in the fight to beat cancer. We work closely with academia and industry to bridge the gap between research and the market, delivering maximum impact for patients. Every penny we make goes back into developing the next breakthroughs, helping bring forward the day when all cancer is conquered.